Furthermore, assessing the expression of AXL and other receptors on remote tissues and assessing for viral SARS-CoV-2 load despite ACE2 inhibition would implicate these alternate receptors as playing central roles in the diverse clinical presentation of COVID-19. This evidence concerns the gene ACE2 and COVID-19.